LambdaTest Unveils the Fourth Edition of the Testµ ('TestMu') Conference in 2025
13.8.2025 18:00:00 CEST | Business Wire | Press Release
LambdaTest, a leading GenAI-native quality engineering platform, is excited to unveil the 4th edition of its flagship Testµ (‘TestMu’) Conference, taking place virtually from August 19–21, 2025. This year’s event is set to host over 50,000 quality, engineering, and DevOps professionals from more than 120 countries, making it one of the largest online global gatherings dedicated to the future of quality engineering.
Testµ (‘TestMu’) Conference 2025 is designed to explore cutting-edge trends, emerging tools, and breakthrough innovations shaping the world of technology. With an esteemed lineup of 100+ global speakers, the conference will feature some of the most influential voices in tech, including Angie Jones, Global Vice President of Developer Relations of Block; Bratin Saha, Chief Product and Technology Officer of DigitalOcean; Dana Lawson, Chief Technology Officer of Netlify; Luis Héctor Chávez, Chief Technology Officer of Replit; Subba Ramaswamy, Managing Director of Accenture; and T.R. Vishwanath, Co-Founder and CTO of Glean.
"In the spirit of 'μ' — the micro that makes the macro matter — Testμ 2025 is where precision meets perspective," said Sachin Sharma, Senior Manager SDET at Adidas and one of the speakers at the 2025 edition. “It's not just about finding bugs; it's about reframing problems, sharpening decisions, and elevating every outcome. Whether you're a tester, developer, or delivery leader, join us to explore the details that define excellence and the ideas that shape the future," he added.
Over three days, attendees will have access to 60+ sessions, including keynotes, interactive workshops, fireside chats, and panel discussions on topics including Generative AI, automation at scale, test frameworks, mobile testing, API testing, AI in software testing, visual testing, accessibility testing, tools and technologies in quality & engineering, technology leadership strategies, and much more. These sessions are designed to foster insightful conversations, hands-on learning, and the exchange of strategic ideas to tackle the future of testing in a rapidly evolving technological landscape.
“TestMu Conference 2025 is LambdaTest's flagship, annual conference built for the community, by the community,” said Asad Khan, CEO and Co‑Founder of LambdaTest. "This conference brings together a community of visionaries, disruptors, and changemakers committed to reshaping the future of engineering and quality. It’s not just an event, it’s a platform for all of us to connect, learn, and inspire one another. At LambdaTest, we’re excited to share how we’re driving innovation in software testing through collaboration, and the TestMu Conference is one such initiative. Let’s break new ground and build a future where software quality is the cornerstone of success."
The conference also provides unparalleled opportunities for peer networking, hands-on learning, and live challenges with exciting prizes. Testμ Conference 2025 also has a rich ecosystem of partners, including Accenture, Wipro, Cognizant, CircleCI, Elastic, Planit, Netlify, Microsoft, and many others.
Registration for the conference is now open. For more details, including the full event schedule, speaker lineup, and topics covered, visit: https://www.lambdatest.com/testmuconf-2025.
About LambdaTest
LambdaTest is a GenAI-powered Quality Engineering Platform that empowers teams to test intelligently, smarter, and ship faster. Built for scale, it offers a full-stack testing cloud with 10K+ real devices and 3,000+ browsers.
With AI-native test management, MCP servers, and agent-based automation, LambdaTest supports Selenium, Appium, Playwright, and all major frameworks. AI Agents like HyperExecute and KaneAI bring the power of AI and cloud into your software testing workflow, enabling seamless automation testing with 120+ integrations.
LambdaTest Agents accelerate your testing throughout the entire SDLC, from test planning and authoring to automation, infrastructure, execution, RCA, and reporting.
For more information, please visit https://lambdatest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813614117/en/
Contacts
press@lambdatest.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom